ATE154641T1 - Neues physiologisch aktives schweinepeptid (cnp- 53) - Google Patents
Neues physiologisch aktives schweinepeptid (cnp- 53)Info
- Publication number
- ATE154641T1 ATE154641T1 AT91111629T AT91111629T ATE154641T1 AT E154641 T1 ATE154641 T1 AT E154641T1 AT 91111629 T AT91111629 T AT 91111629T AT 91111629 T AT91111629 T AT 91111629T AT E154641 T1 ATE154641 T1 AT E154641T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- cnp
- swine
- physiologically active
- new physiologically
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 title 1
- 101800000060 C-type natriuretic peptide Proteins 0.000 title 1
- 101800000433 CNP-53 Proteins 0.000 title 1
- 241000282898 Sus scrofa Species 0.000 title 1
- UHSBKBYWHCBDCJ-DYGWFTAGSA-N natriuretic peptide, c-type Chemical compound N1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN)CSSC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H]1CC1=CC=CC=C1 UHSBKBYWHCBDCJ-DYGWFTAGSA-N 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000001452 natriuretic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2186582A JP2930380B2 (ja) | 1990-07-13 | 1990-07-13 | ブタ由来新規生理活性ペプチド（ｃｎｐ―５３） |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE154641T1 true ATE154641T1 (de) | 1997-07-15 |
Family
ID=16191066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91111629T ATE154641T1 (de) | 1990-07-13 | 1991-07-12 | Neues physiologisch aktives schweinepeptid (cnp- 53) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5340920A (de) |
| EP (1) | EP0466174B1 (de) |
| JP (1) | JP2930380B2 (de) |
| AT (1) | ATE154641T1 (de) |
| DE (1) | DE69126568T2 (de) |
| DK (1) | DK0466174T3 (de) |
| ES (1) | ES2104635T3 (de) |
| GR (1) | GR3024581T3 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169573C (zh) | 1998-09-28 | 2004-10-06 | 参天制药株式会社 | 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂 |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| KR20070007842A (ko) | 2004-03-31 | 2007-01-16 | 카즈와 나카오 | 신장증가용 조성물 |
| CN1960758B (zh) * | 2004-03-31 | 2014-10-22 | 中外制药株式会社 | 关节炎的治疗剂或预防剂 |
| ATE505551T1 (de) | 2004-04-21 | 2011-04-15 | Enobia Pharma Inc | Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen |
| JP2011504506A (ja) | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｃ型ナトリウム利尿ペプチドの変異体 |
| HUE032582T2 (en) | 2009-05-20 | 2017-09-28 | Biomarin Pharm Inc | Variants of c-type natriuretic peptide |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| CA2852874A1 (en) | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| WO2016090251A1 (en) | 2014-12-05 | 2016-06-09 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| JP6993961B2 (ja) | 2015-08-17 | 2022-01-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼの製造 |
| EP3355904A4 (de) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| CA3008017C (en) | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US11186832B2 (en) | 2016-04-01 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
| WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
| US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| JP2020512363A (ja) | 2017-03-31 | 2020-04-23 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| EP3833377B1 (de) | 2018-08-10 | 2023-11-22 | Alexion Pharmaceuticals, Inc. | Knochenheilung an implantaten mittels alkalischer phosphatase |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| EP4291224A4 (de) | 2021-02-12 | 2025-01-01 | Alexion Pharmaceuticals, Inc. | Alkalische phosphatasepolypeptide und verfahren zur verwendung davon |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2544929B2 (ja) * | 1987-06-17 | 1996-10-16 | 第一化学薬品 株式会社 | 新規生理活性ペプチド |
| US5114923A (en) * | 1988-05-31 | 1992-05-19 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
-
1990
- 1990-07-13 JP JP2186582A patent/JP2930380B2/ja not_active Expired - Lifetime
-
1991
- 1991-07-12 DE DE69126568T patent/DE69126568T2/de not_active Expired - Lifetime
- 1991-07-12 ES ES91111629T patent/ES2104635T3/es not_active Expired - Lifetime
- 1991-07-12 US US07/728,221 patent/US5340920A/en not_active Expired - Lifetime
- 1991-07-12 EP EP91111629A patent/EP0466174B1/de not_active Expired - Lifetime
- 1991-07-12 DK DK91111629.1T patent/DK0466174T3/da active
- 1991-07-12 AT AT91111629T patent/ATE154641T1/de not_active IP Right Cessation
-
1997
- 1997-08-29 GR GR970402223T patent/GR3024581T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3024581T3 (en) | 1997-12-31 |
| ES2104635T3 (es) | 1997-10-16 |
| EP0466174B1 (de) | 1997-06-18 |
| EP0466174A1 (de) | 1992-01-15 |
| DE69126568D1 (de) | 1997-07-24 |
| DK0466174T3 (da) | 1998-01-12 |
| US5340920A (en) | 1994-08-23 |
| JP2930380B2 (ja) | 1999-08-03 |
| JPH0474198A (ja) | 1992-03-09 |
| DE69126568T2 (de) | 1997-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE154641T1 (de) | Neues physiologisch aktives schweinepeptid (cnp- 53) | |
| NO167295C (no) | Fremgangsmaate for fremstilling av et terapeutisk aktivt peptid. | |
| DK0573551T3 (da) | Serinrige peptidlinkere | |
| DE69535963D1 (de) | LHRH antagonistische Peptide | |
| EP0475394A3 (en) | Rat c-type natriuretic peptide cdna and precursor protein | |
| SE8605189L (sv) | Nya kalcitoninderivat | |
| NO971621L (no) | Keratinocyttvekstfaktoranaloger | |
| BG97123A (bg) | Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа | |
| SE9603468D0 (sv) | New compounds | |
| SE7712634L (sv) | Ny polypeptid med serumkalciumreducerande aktivitet | |
| DK0490383T3 (da) | Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf | |
| AU2254588A (en) | Biologically active segments of several growth hormones | |
| SE9603461D0 (sv) | New compounds | |
| ATE153378T1 (de) | Heparin bindender wachstumsfaktor | |
| SE9603463D0 (sv) | New compounds | |
| SE9603462D0 (sv) | New compounds | |
| DK53290A (da) | Syntetiske gaer-leader-peptider |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |